A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug–Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy-Reference-Cited by-同舟云学术

A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug–Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy

Published:2020-04-30 Issue:6 Volume:34 Page:661-672
ISSN:1172-7047
Container-title:CNS Drugs
language:en
Short-container-title:CNS Drugs

Author:

Ben-Menachem Elinor^ORCID,Gunning Boudewijn,Arenas Cabrera Carmen María,VanLandingham Kevan,Crockett Julie,Critchley David,Wray Louise,Tayo Bola,Morrison Gilmour,Toledo Manuel

Funder

GW Research Ltd, Cambridge, UK

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Psychiatry and Mental health,Clinical Neurology

Link

https://link.springer.com/content/pdf/10.1007/s40263-020-00726-4.pdf

Reference44 articles.

1. Epidiolex® (cannabidiol) oral solution, CV [prescribing information]. Carlsbad, CA: Greenwich Biosciences, Inc. 2018.

2. GW Pharmaceuticals, plc. Epidyolex 100 mg/ml oral solution: summary of product characteristics (SmPC). 2019.

3. Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376:2011–20.